Prognostic Value of the Interval Between Relapse and Therapy Initiation in Diffuse Large B-Cell Lymphoma Patients. Analysis From the Czech Lymphoma Study Group Database

Hematological Oncology - United Kingdom
doi 10.1002/hon.83_2631
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Prognostic Biomarkers in Diffuse Large B-Cell Lymphoma

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2006English

Molecular Landscape of Relapse/Refractory Diffuse Large B-Cell Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Prognostic Value of Baseline FDG Pet Parameters in High Risk Diffuse Large B-Cell Lymphoma Patients

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Plasma Immunoprofiling of Patients With High-Risk Diffuse Large B-Cell Lymphoma: A Nordic Lymphoma Group Study

Blood Cancer Journal
OncologyHematology
2016English

Diffuse Large B-Cell Lymphoma

2020English

Primary Breast Diffuse Large B-Cell Lymphoma. Clinical Features and Outcome in 55 Patients. Polish Lymphoma Research Group Study

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Prognostic Nomogram for Overall Survival in Patients With Diffuse Large B‐Cell Lymphoma

Oncologist
Cancer ResearchMedicineOncology
2019English

The Graft-Versus-Lymphoma Effect in Diffuse Large B-Cell Lymphoma

Biology of Blood and Marrow Transplantation
TransplantationHematology
2015English

The Kyoto Prognostic Index for Patients With Diffuse Large B-Cell Lymphoma in the Rituximab Era

Blood
BiochemistryImmunologyCell BiologyHematology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy